Industries > Pharma > Global Anti-Obesity Drugs Market Forecast 2017-2027

Global Anti-Obesity Drugs Market Forecast 2017-2027

Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics and Others

PUBLISHED: 12 January 2017
PAGES: 205
PRODUCT CODE: PHA0161
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0161 Categories: ,

The global anti-obesity drugs market is expected to grow at a CAGR of 27.1% in the first half of the forecast period and CAGR of 38.7% in the second half of the forecast period. The market is expected to grow at a CAGR of 32.8% from 2016 to 2027. The market is estimated at $1,058 million in 2016, $3,513 million in 2021, and $24,063 million in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 205-page report you will receive 78 tables and 140 figures – all unavailable elsewhere.

The 205-page report provides clear detailed insight into the global anti-obesity drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Global Anti-Obesity Drugs Market Forecast 2017-2027

Report Scope
Global Anti-Obesity Drugs market forecasts from 2017-2027

• Anti-Obesity Drugs National market forecasts from 2017-2027, covering:
– United States
– Germany
– France
– United Kingdom
– Italy
– Spain
– Japan
– China
– India
– Brazil
– Russia
– RoW

• Anti-Obesity Drugs submarket forecasts from 2017-2027, by Mechanisms of Action:
– Incretin mimetics/GLP-1 agonists
– SNDRIs
– Lipase inhibitors
– Serotonin receptor agonists
– Sympathomimetic-GABA receptor agonists
– Sympathomimetics
– Others

• Anti-Obesity Drugs submarket forecasts from 2017-2027, by Duration of Therapy:
– Short-term Drugs
– Long-term Drugs

• Anti-Obesity Drugs submarket forecasts from 2017-2027, segmented by Innovator vs Generic Drugs

• Anti-Obesity Drugs submarket forecasts from 2017-2027, segmented by Prescription vs OTC Drugs

• Analysis of the key factors driving and restraining the growth of the anti-obesity drugs market from 2017-2027

Pricing and Reimbursement overview of the anti-obesity drugs market

• Assessment of selected leading companies that hold major market shares in the anti-obesity drugs market.

Visiongain’s study is intended for anyone requiring commercial analyses for the Anti-Obesity Drugs Market and leading companies. You find data, trends and predictions.

Buy our report today Global Anti-Obesity Drugs Market Forecast 2017-2027: Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics and Others.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Anti-Obesity Drugs Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Anti-Obesity Drugs Market Forecast 2017-2027


Latest Pharma news

“Global Asthma & COPD market set to grow to $49 bn by 2025” says new Visiongain report

The Asthma and COPD market has the potential to bring several blockbuster drugs to the marketplace due to the increasingly segmented sub-groups of patients.

17 February 2020

READ

“Global Rheumatoid Arthritis Drugs market estimated to grow at a CAGR of 0.6% in the second half of the forecast period” says Visiongain report

Another factor driving the growth in the market is the discovery of new molecules that are involved in the disease process, and hence, new strategies for treating the disease.

17 February 2020

READ

Visiongain assesses that the Contract Research Organisations (CROs) market will generate revenues of $38.0 billion in 2020

Global clinical research organizations market was valued at $34.9 billion in 2019 and is projected to grow at a CAGR of 9.5% during the forecast period 2020-2030.

12 February 2020

READ

“Translational Regenerative Medicine market set to grow to $118bn by 2025” says new Visiongain report

The translational regenerative medicine market is expected to grow significantly due to the advances in technology and improvements in regulatory frameworks.

03 February 2020

READ

Categories

Category